Ftse Mib
34.331,39
0,53%
DAX
18.686,60
1,07%
S&P 500
5.206,92
0,37%
NASDAQ
16.336,76
0,21%
Bitcoin
62.019,19
1,35%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kazia Therapeutics Ltd (KZIA) Kazia Therapeutics Ltd (KZIA) Notizie

KZIA

Kazia Therapeutics (KZIA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZIA
DataOraFonteTitoloSimboloCompagnia
01/05/202414:45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
21/03/202413:52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
13/03/202413:00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
21/02/202422:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
21/02/202415:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
21/02/202413:30PR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointNASDAQ:KZIAKazia Therapeutics Ltd
14/02/202421:41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
06/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
18/01/202413:30PR Newswire (US)KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSNASDAQ:KZIAKazia Therapeutics Ltd
15/12/202323:26Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
15/12/202322:49Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
06/12/202300:02PR Newswire (US)Kazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
04/12/202322:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
01/12/202314:00PR Newswire (US)Kazia Therapeutics Announces $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
29/11/202313:01PR Newswire (US)KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNASDAQ:KZIAKazia Therapeutics Ltd
21/11/202313:30PR Newswire (US)KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
20/11/202322:30PR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
15/11/202314:30PR Newswire (US)KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
10/11/202313:01PR Newswire (US)KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
01/11/202312:01PR Newswire (US)KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMANASDAQ:KZIAKazia Therapeutics Ltd
26/10/202313:56Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:KZIAKazia Therapeutics Ltd
23/10/202313:01PR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDYNASDAQ:KZIAKazia Therapeutics Ltd
11/10/202313:01PR Newswire (US)Kazia announces voluntary delisting from ASXNASDAQ:KZIAKazia Therapeutics Ltd
05/10/202313:01PR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGSNASDAQ:KZIAKazia Therapeutics Ltd
29/09/202313:01PR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
06/07/202313:00PR Newswire (US)KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPYNASDAQ:KZIAKazia Therapeutics Ltd
26/06/202313:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:KZIAKazia Therapeutics Ltd
08/06/202313:00PR Newswire (US)KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMANASDAQ:KZIAKazia Therapeutics Ltd
25/05/202313:01PR Newswire (US)KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOTNASDAQ:KZIAKazia Therapeutics Ltd
14/04/202313:01PR Newswire (US)KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTNASDAQ:KZIAKazia Therapeutics Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZIA

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network